Pilocytic astrocytoma

Overview

Pilocytic astrocytoma (PA) is a distinct, well-circumscribed, slow-growing (low-grade) brain tumor that arises from star-shaped glial cells called astrocytes. Classified by the World Health Organization (WHO) as a Grade I neoplasm, it is the most common glioma in children and adolescents, though it can occur at any age. Unlike diffuse astrocytomas (Grade II–IV), pilocytic astrocytomas do not infiltrate surrounding brain tissue aggressively; instead, they push adjacent structures aside, forming a discrete mass often with a cystic component.

The term “pilocytic” derives from the Latin pilus (hair), describing the long, hair-like bipolar processes (Rosenthal fibers) seen on microscopic examination. Because of its benign biological behavior and high responsiveness to surgical resection, PA carries one of the most favorable prognoses of all central nervous system (CNS) tumors.

Pilocytic astrocytoma is a benign (non-cancerous), slow-growing brain tumor with a very high cure rate, particularly when complete surgical removal is achieved.

Epidemiology: Who Is Affected?

Etiology and Molecular Pathogenesis

Pilocytic astrocytoma is fundamentally a disease of the MAPK (Mitogen-Activated Protein Kinase) signaling pathway. Unlike high-grade gliomas driven by mutations in TP53, IDH, or EGFR, PA is defined by a single, dominant driver alteration leading to constitutive activation of the RAF-MEK-ERK cascade.

Key Molecular Drivers

Why this matters: The near-universal activation of the MAPK pathway provides a unified biological explanation for the tumor’s growth and, crucially, opens the door for targeted molecular therapies (MEK inhibitors like selumetinib, BRAF inhibitors like dabrafenib) for unresectable or recurrent disease.

Clinical Presentation: Symptoms

Symptoms of pilocytic astrocytoma are highly dependent on tumor location, size, and the resulting mass effect or obstructive hydrocephalus. Because these tumors grow slowly, symptoms often develop insidiously over months.

1. Posterior Fossa / Cerebellar Tumors (Most Common)

• Obstructive Hydrocephalus (Urgent): Blockage of the fourth ventricle or foramina of Luschka/Magendie causes CSF buildup.
• Symptoms: Morning headache (worse lying flat), projectile vomiting (non-bilious), lethargy, irritability, papilledema (optic disc swelling), cranial nerve VI palsy (diplopia/esotropia).
• Cerebellar Dysfunction (Mass Effect):
• Ataxia: Wide-based, unsteady gait; trunkal titubation.
• Dysmetria / Intention Tremor: Past-pointing on finger-nose testing.
• Dysdiadochokinesia: Inability to perform rapid alternating movements.
• Nystagmus: Horizontal or gaze-evoked.
• Cranial Nerve Signs: Compression of brainstem → facial weakness (CN VII), hearing loss (CN VIII), swallowing difficulty (CN IX/X).

2. Optic Pathway / Hypothalamic / Suprasellar Tumors

• Visual Disturbances: Progressive vision loss, bitemporal hemianopsia (chiasmal compression), decreased visual acuity, color blindness, afferent pupillary defect (Marcus Gunn pupil).
• Endocrine Dysfunction (Hypothalamic involvement):
• Growth Failure: Growth hormone deficiency (most common).
• Precocious Puberty / Delayed Puberty: Gonadotropin dysregulation.
• Diabetes Insipidus: Polyuria/polydipsia (posterior pituitary stalk effect).
• Obesity / Hypothalamic Syndrome: Dysregulation of satiety/thermoregulation.
• Diencephalic Syndrome (Infants): Emaciation despite normal caloric intake, hyperalertness, euphoria, nystagmus.

3. Brainstem Tumors (Pons, Medulla, Midbrain)

• Multiple Cranial Nerve Palsies: Facial asymmetry, double vision (CN VI), dysphagia/dysarthria (CN IX/X), hearing loss (CN VIII).
• Long Tract Signs: Hemiparesis (corticospinal tract), sensory loss, hyperreflexia, Babinski sign.
• Hydrocephalus: If tectal plate/com aqueduct compressed (Parinaud’s syndrome: upgaze palsy, convergence-retraction nystagmus).

4. Cerebral Hemispheric Tumors

• Seizures: Most common presenting symptom (focal aware or impaired awareness, may generalize).
• Focal Neurological Deficits: Hemiparesis, aphasia (dominant hemisphere), neglect (non-dominant), visual field cuts.
• Headache: Non-specific, tension-type or migraine-like.

5. Spinal Cord Tumors (Rare)

• Pain: Local back pain, radicular pain (shooting down limb/dermatome).
• Myelopathy: Progressive weakness, sensory level, bowel/bladder dysfunction (urinary retention/incontinence).
• Scoliosis: Torticollis or spinal deformity in children (paraspinal muscle imbalance).

Red Flags Requiring Immediate Evaluation

How Does It Look? (Radiology & Pathology)

This section details the characteristic imaging and histological appearance that allows radiologists and pathologists to diagnose PA, often before surgery.

A. Neuroimaging: Magnetic Resonance Imaging (MRI)

MRI with and without gadolinium contrast is the gold standard. CT is used acutely for hydrocephalus assessment but lacks soft tissue detail.

1. Classic Cerebellar Pilocytic Astrocytoma (“The Textbook Case”)

2. Variant Imaging Patterns (Location Dependent)

• Optic Pathway / Hypothalamic: Fusiform enlargement of optic nerve/chiasm/tracts (“kinking” of nerve). Intense homogeneous enhancement. Often extends into hypothalamus. NF1-associated tumors may show less enhancement/T2 hyperintensity but similar morphology.
• Brainstem (Tectal/Exophytic): Dorsally exophytic growth into 4th ventricle (tectal) or eccentric expansion of pons/medulla. Well-circumscribed. Enhancement variable (solid = strong; cystic = rim).
• Cerebral Hemisphere: Often solid or predominantly solid with less cystic change. May have “cyst with mural nodule” but solid tumors are common. Can mimic low-grade diffuse glioma (Grade II) or glioblastoma (if atypical features), but usually well-circumscribed.
• Spinal Cord: Well-circumscribed, eccentric, expansile lesion. Syrinx (syringomyelia) rostral/caudal to tumor is common (~50%). Intense enhancement.

3. Advanced Imaging (Ancillary)

• MR Spectroscopy (MRS): Elevated Choline (Cho) (membrane turnover), decreased NAA (neuronal loss), variable Lactate/Lipid (in cystic fluid/necrosis). Not diagnostic but supports neoplastic process.
• Perfusion (DSC/DCE): Low relative cerebral blood volume (rCBV) compared to high-grade gliomas (Grade III/IV). Helps distinguish from anaplastic astrocytoma/GBM.
• Diffusion (DWI/ADC): Cyst fluid = high ADC (free diffusion). Solid component = variable, usually not markedly restricted (unlike medulloblastoma/lymphoma).

Radiology Pearl: The combination of a cystic cerebellar mass with a vividly enhancing mural nodule and minimal edema in a child** is pathognomonic for Pilocytic Astrocytoma.

B. Neuropathology: Microscopic & Molecular Features

Diagnosis is confirmed by histopathological examination of tissue (biopsy or resection). The 2021 WHO CNS5 classification defines PA as a “circumscribed astrocytic glioma” defined by MAPK pathway activation.

1. Histology (H&E Stain)

2. Immunohistochemistry (IHC)

3. Molecular Diagnostics (Confirmatory)

• FISH (Fluorescence In Situ Hybridization): Break-apart probe for BRAF (7q34) detects KIAA1549-BRAF fusion (split signals). Gold standard for fusion detection.
• RNA Sequencing / NGS Panels: Detects KIAA1549-BRAF fusion, FGFR1 mutations/fusions, NTRK fusions, RAF1 fusions. Preferred for comprehensive profiling.
• Methylation Profiling: “Epigenetic classifier” assigns tumor to “Pilocytic Astrocytoma” methylation class with high confidence. Resolves diagnostically challenging cases (e.g., solid supratentorial PA vs. Glioblastoma vs. High-grade astrocytoma with piloid features).

4. Differential Diagnosis (Pathology)

Diagnostic Workup: Step-by-Step Algorithm

1. Clinical Assessment: History, Neurological Exam (cranial nerves, gait, fundoscopy for papilledema), Endocrine screen (if suprasellar).
2. Neuroimaging: MRI Brain (or Spine) with/without Gadolinium (Standard protocol: T1, T2, FLAIR, DWI, T1+C+, SWI). CT Head if acute hydrocephalus/emergency.
3. Multidisciplinary Tumor Board Review: Neurosurgery, Neuro-oncology, Neuroradiology, Neuropathology, Radiation Oncology.
4. Surgical Planning:

• Resectable: Gross Total Resection (GTR) is Goal #1.
• Unresectable/Deep (Brainstem, Hypothalamus, Optic Chiasm): Stereotactic Biopsy (framed or frameless/robot-assisted) for molecular diagnosis.

1. Histopathology & Molecular Profiling: H&E, IHC panel (GFAP, Ki-67, BRAF V600E, pERK, H3K27M, IDH1, ATRX), FISH/NGS for BRAF fusion/other drivers.
2. Staging (Baseline):

• MRI Spine (if brain tumor, to rule out drop metastases – rare in PA but standard baseline).
• Lumbar Puncture (CSF Cytology) Only after mass effect/hydrocephalus resolved (risk of herniation). Rarely positive in PA.
• Ophthalmology Exam (Visual fields, acuity, OCT) for optic pathway tumors.
• Endocrine Panel (GH, IGF-1, TSH, fT4, LH, FSH, Testosterone/Estradiol, Cortisol, ADH) for suprasellar tumors.

Treatment Strategies

Management is risk-adapted based on Location, Resectability, Age, and Molecular Profile.

1. Surgery: The Curative Cornerstone

• Goal: Gross Total Resection (GTR) = Complete removal of enhancing solid tumor + cyst wall (if feasible).
• Outcome: GTR → >90% 10-year Progression-Free Survival (PFS). No adjuvant therapy needed.
• Techniques: Microsurgery, Neuronavigation, Intraoperative MRI/Ultrasound, Neurophysiological Monitoring (MEP/SSEP/BAEP for brainstem/cerebellum), Fluorescence (5-ALA rarely used in PA as low grade, but ICG videoangiography for vessels).
• Subtotal Resection (STR) / Biopsy Only: Residual tumor → High risk of progression. Observation vs. Adjuvant Therapy.

Surgical Nuances by Location

2. Adjuvant Therapy: When Surgery Isn’t Enough

Indications: Subtotal Resection (STR) with progression, Unresectable location (optic pathway, hypothalamus, deep brainstem) with symptomatic progression, Recurrence after surgery. Age < 3 years: Avoid radiation if possible.

A. Chemotherapy (First Line for Children / Low-Grade Glioma Protocols)

• Carboplatin + Vincristine (CV): Standard backbone (COG ACNS0221 / SIOP LGG 2004). ~12–18 months duration. Good tolerability.
• Vinblastine Monotherapy: Alternative (lower toxicity, weekly dosing). Effective for optic pathway/hypothalamic.
• Temozolomide (TMZ): Used in older children/adolescents/adults. Oral, well-tolerated.
• TPCV (Thiotepa, Procarbazine, Lomustine, Vincristine): Historical high-dose regimen; largely replaced by CV/TMZ due to toxicity (infertility, secondary malignancies).

B. Targeted Therapy (The Modern Era – MAPK Inhibition)

Revolutionized management of unresectable/recurrent PA.

Toxicities of MEK Inhibitors (Class Effect):

• Dermatologic: Acneiform rash, photosensitivity, paronychia.
• Ocular: Serous Retinopathy / Retinal Vein Occlusion (Monitor OCT/Visual acuity q3mo).
• Cardiac: Asymptomatic LVEF reduction (Echo/MUGA baseline + q3mo).
• Musculoskeletal: CPK elevation, myalgias, Growth plate toxicity (premature physeal closure) in children → Monitor height/limb length.
• GI: Diarrhea, nausea.

C. Radiation Therapy (RT)

• Role: Salvage therapy for progressive disease failing chemo/targeted therapy. Curative intent for recurrent PA.
• Techniques: Focal Conformal RT (3D-CRT / IMRT / Proton Beam Therapy). Dose: 50.4 – 54 Gy (1.8 Gy/fx).
• Pediatric Consideration: Avoid < 3-5 years if possible (neurocognitive decline, endocrine deficits, vasculopathy, secondary malignancies). Proton Therapy preferred for children (lower integral dose to developing brain).
• Stereotactic Radiosurgery (SRS/SRT): Option for small (<3cm), well-defined recurrent lesions (esp. cerebral), but risk of cyst expansion/edema.

Follow-Up & Survivorship Care Plan

Because PA is a chronic condition with risk of very late recurrence (10–20+ years), lifelong surveillance is standard.

Surveillance MRI Schedule (Post-GTR, No Residual)

Note: If on targeted therapy (MEKi), MRI q3mo initially. If residual tumor stable, interval may extend.

Multidisciplinary Long-Term Monitoring

Prognosis & Outcomes

Pilocytic astrocytoma has the best prognosis of all glial neoplasms.

Survival Statistics (Modern Series)

• Overall Survival (OS) at 10 years: > 95% (All comers).
• Progression-Free Survival (PFS) at 10 years:
• GTR: 90–95%.
• STR/Biopsy: 30–50% (without adjuvant therapy); 60–75% (with chemo/targeted therapy).
• Cause of Death: Rarely tumor progression (usually in unresectable midline/high-grade variants). More commonly: Treatment complications (hydrocephalus, shunt dependence), secondary malignancies (post-RT), or unrelated causes.

Message of Hope: The vast majority of children and adults diagnosed with pilocytic astrocytoma become long-term survivors** with good functional outcomes. The focus of modern care is maximizing quality of survival (neurocognition, endocrine health, vision, independence).

Special Clinical Scenarios

1. Pilocytic Astrocytoma in Neurofibromatosis Type 1 (NF1)

• Incidence: 15–20% of NF1 patients develop Optic Pathway Glioma (OPG), majority are PA.
• Natural History: Indolent. Only ~30–50% require treatment. Many stabilize or regress spontaneously in adolescence.
• Management: “Watch and Wait” (Active Surveillance) is standard for asymptomatic/non-progressive tumors. Serial MRI (q3-6mo initially) + Ophthalmology (q3-6mo).
• Treatment Trigger: Documented radiological progression PLUS clinical decline (vision loss, proptosis, hypothalamic syndrome).
• First Line: Carboplatin/Vincristine or Vinblastine. Selumetinib (MEKi) is FDA-approved for symptomatic, inoperable NF1-PN (plexiform neurofibromas) and shows high efficacy in NF1-OPG.

2. “Anaplastic” Pilocytic Astrocytoma / High-Grade Astrocytoma with Piloid Features

• Rare subset (<5%) showing high mitotic activity, necrosis, or microvascular proliferation retaining piloid morphology and MAPK alteration.
• Molecular hallmark: CDKN2A/B Homozygous Deletion (often with ATRX loss or TERT promoter mutation).
• WHO CNS5 Classification: Graded WHO Grade 3 or 4 (depending on features) as “High-grade astrocytoma with piloid features” or “Anaplastic pilocytic astrocytoma” (legacy term).
• Treatment: Aggressive – GTR + Radiation Therapy + Chemotherapy (TMZ). Worse prognosis than classic PA.

3. Pilomyxoid Astrocytoma (PMA)

• Distinct entity (WHO Grade 2). Monophasic, angiocentric, myxoid matrix. No Rosenthal fibers/EGBs.
• Age: Infants/Young children (<2 yrs).
• Location: Hypothalamus/Optic chiasm (suprasellar) predominant.
• Behavior: More aggressive – higher local recurrence, CSF dissemination (drop metastases) risk (~15-20%).
• Treatment: Max safe resection + Chemo (CV) ± RT (delayed). MEK inhibitors active.

4. Pregnancy and PA

• Hormonal influence (progesterone/estrogen receptors rare but reported) may cause growth acceleration during pregnancy.
• Management: MRI surveillance trimesterly if known residual. Surgery deferred to 2nd trimester if symptomatic. Vaginal delivery usually safe unless significant hydrocephalus/icipital pressure.

Patient & Caregiver Resources / Quality of Life

Living with a brain tumor diagnosis extends beyond medical treatment.

• School/Work Accommodations: 504 Plan / IEP (USA) for processing speed, memory, fatigue, visual/motor deficits. Neuropsych testing guides this.
• Fatigue Management: “Pacing” strategies, scheduled rests, sleep hygiene.
• Seizure Control: Rescue meds (benzodiazepines), daily AEDs if history of seizures. Driving laws vary by jurisdiction (usually seizure-free 6–12 months).
• Financial Toxicity: Social work navigation for disability, insurance, drug assistance programs (manufacturer co-pay cards for Selumetinib/Dabrafenib/Trametinib).
• Support Organizations:
• Pediatric Brain Tumor Foundation (PBTF)
• Children’s Brain Tumor Foundation (CBTF)
• American Brain Tumor Association (ABTA)
• National Brain Tumor Society (NBTS)
• Neurofibromatosis Network / Children’s Tumor Foundation (CTF) (for NF1 families)

Frequently Asked Questions (FAQ)

Q: Is pilocytic astrocytoma cancer?

A: Technically, it is a neoplasm (tumor). Pathologists classify it as WHO Grade 1, which denotes “benign” biological behavior (slow growth, non-infiltrative, low mitotic rate). However, because it grows in the confined skull, it can cause life-threatening mass effect. Clinicians often use “low-grade glioma” or “brain tumor” rather than “cancer” to avoid the stigma and implication of systemic malignancy associated with high-grade tumors.

Q: Can it spread to other parts of the body?

A: Extremely rare. Classic PA stays within the CNS. CSF dissemination (drop metastases) occurs in <2% of classic PA (higher in PMA/anaplastic variants). Systemic metastasis outside CNS is virtually non-existent.

Q: Will my child need a shunt for hydrocephalus?

A: Often, resecting the tumor cures the hydrocephalus by unblocking CSF pathways. An Endoscopic Third Ventriculostomy (ETV) may be performed at the time of tumor resection if needed. Permanent VP shunts are required in a minority (~10-20%) where CSF absorption is permanently impaired or tumor is unresectable (tectal).

Q: Does the tumor come back after complete removal?

A: Recurrence after GTR is low (~5-10% at 10 years). However, late recurrences (10-20+ years) are documented. This mandates long-term surveillance MRI.

Q: Are there lifestyle changes or diets that shrink the tumor?

A: No scientific evidence supports specific diets (ketogenic, sugar-free, supplements) curing PA. A balanced diet supports healing. Always discuss supplements with your neuro-oncologist (e.g., antioxidants may interfere with RT/chemo; St. John’s Wort interacts with many drugs).

Q: Can adults get pilocytic astrocytoma?

A: Yes. While peak is pediatric, ~15-20% are diagnosed in adults (20-40 yrs). Adults more often have supratentorial (cerebral) location, solid morphology, and BRAF V600E mutation. Prognosis remains excellent with GTR.

Glossary of Terms

References

1. Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C., Ng, H.K., Pfister, S.M., Reifenberger, G., Soffietti, R., von Deimling, A. and Ellison, D.W. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231–1251. https://doi.org/10.1093/neuonc/noab106.
2. Jones, D.T.W., Hutter, B., Jager, N., Korshunov, A., Kool, M., Warnatz, H.J., Zichner, T., Lambert, S.R., Ryzhova, M., Quang, D.A.K., Stutz, A.M., Rhyzova, M., Bender, S., Sturm, D., Lasitschka, B., Milde, T., Hovestadt, V., Zapatka, M., Reinhardt, A., Schefzyk, S., Sebastian, C., Pfaff, E., Stark, S., Venn, N.C., Titov, S., Moritz, J., Jahn, D., Weber, U.D., Eils, J., Wittmann, A., Remke, M., Sievert, A.J., von Deimling, A., Korbel, J.O., Lichter, P., Pfister, S.M. and Korshunov, A. (2013) ‘Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma’, Nature Genetics, 45(8), pp. 927–932. https://doi.org/10.1038/ng.2682.
3. Cin, H., Meyer, C., Herr, R., Janzarik, W.G., Moritz, J., Bruch, H., Jox, R., Felsberg, J., Korshunov, A., Hovestadt, V., Jones, D.T.W., Pfister, S.M., Reifenberger, G., Paulus, W., Waha, A., von Deimling, A. and Wirsching, H.G. (2011) ‘Oncogenic BRAF fusions in pilocytic astrocytoma’, Acta Neuropathologica, 122(2), pp. 155–161. https://doi.org/10.1007/s00401-011-0848-7.
4. Sievert, A.J., Jackson, E.M., Gai, X., Hakonarson, H., Judkins, A.R., Resnick, A.C., Biegel, J.A., Ming, X. and Tooke, L. (2010) ‘Duplication of 7q34 in pediatric low-grade astrocytomas’, Neuro-Oncology, 12(6), pp. 625–630. https://doi.org/10.1093/neuonc/noq011.
5. Jakacki, R.I., Dhall, G., Buxton, A., Fouladi, M., Dunkel, I.J., Bergthold, G., Packer, R.J., Goldman, S., Allen, J.C., Blaney, S.M., Gilbertson, R.J. and Gajjar, A. (2016) ‘Children’s Oncology Group ACNS0221: A phase II study of carboplatin and vincristine for children with newly diagnosed low-grade glioma’, Journal of Clinical Oncology, 34(15_suppl), pp. 10503–10503. https://doi.org/10.1200/JCO.2016.34.15_suppl.10503.
6. Dombi, E., Baldwin, A., Marcus, L.J., Fisher, M.J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L., Duda, J., Hull, K., Schorry, E., Wolters, P.L., Baldwin, A., Toledo-Tamula, M.A., Vranceanu, A.M., Merker, V., Avery, R.A., Packer, R.J., Widemann, B.C. and the SPRINT Consortium (2019) ‘Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas’, New England Journal of Medicine, 380(1), pp. 100–110. https://doi.org/10.1056/NEJMoa1712854. Note: Selumetinib data extrapolated to sporadic PA via LOGIC trial.
7. Kieran, M.W., Goumnerova, L.C., Manley, P.E., Scott, R.M., Jaju, A., Kim, A., Ullrich, N.J., van der Woude, M., Allen, J.C., Turner, C.D., Goldman, S., Packer, R.J., Boyett, J.M., Broniscer, A., Prados, M.D., Pollack, I.F., Wisoff, J.H., Dunkel, I.J., Fouladi, M., Goldman, S., Geyer, J.R., Li, X., Dalton, J., Krskova, L., Hargrave, D., Bartels, U., Handscombe, J., Hukin, J., Keating, R.F., Laughlin, S., Leonard, J.R., McGuire-Cullen, T., O’Brien, M., Poussaint, T.Y., Santi, M., Shrieve, D.C., Sposto, R., Stewart, C.F., Tabori, U., Vezina, G., Weprin, B., Wise, K., Zeltzer, P. and Zimmerman, R.A. (2019) ‘A phase II trial of selumetinib in children with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium study’, Neuro-Oncology, 21(7), pp. 936–944. https://doi.org/10.1093/neuonc/noz004.
8. Hargrave, D., Bartels, U., Bouffet, E., Broniscer, A., Carret, A.S., Cohen, K., Dunkel, I., Fangusaro, J., Grill, J., Jakacki, R., Jones, C., Kilburn, L., Kieran, M., Lassaletta, A., Lober, R., Massimino, M., Merchant, T., Packer, R., Pfister, S., Pollack, I., Prados, M., Rodriguez-Galindo, C., Tabori, U., van Vuurden, D., Warren, K., Witt, O. and Bouffet, E. (2018) ‘Pediatric low-grade glioma: current standards and future directions’, Neuro-Oncology, 20(5), pp. 612–623. https://doi.org/10.1093/neuonc/noy001.
9. Rodrigues, F.D., Sredni, S.T., Timms, A.E., Tomita, T. and Goldman, S. (2019) ‘Pilocytic astrocytoma: from molecular pathogenesis to targeted therapies’, Frontiers in Oncology, 9, p. 345. https://doi.org/10.3389/fonc.2019.00345.
10. Quinn, J.A., Reaman, G.H., Friedman, H.S., Biegel, J.A., Walter, A.W., Hassall, T., Rorke, L.B., Li, X., Epstein, F., Gilles, F.H., Geyer, J.R., Heideman, R.L., Krischer, J.P., Kun, L.E., Mulne, A., Phillips, P., Pollack, I.F., Prados, M.D., Relling, M.V., Sanford, R.A., Schut, L., Timmons, C., Tomita, T., Trevenen, C., Zimmerman, R. and Boyett, J.M. (2001) ‘Phase II trial of carboplatin and vincristine in children with newly diagnosed low-grade astrocytoma: a Children’s Cancer Group study’, Journal of Clinical Oncology, 19(9), pp. 2440–2447. https://doi.org/10.1200/JCO.2001.19.9.2440.
11. Ater, J.L., Zhou, T., Holmes, E., Mazewski, C.M., Booth, T.N., Freyer, D.R., Gajjar, A., Heideman, R.L., Huh, W.W., Lau, K., Li, X., McNeil, D.E., Mehta, M., Pollack, I.F., Prados, M.D., Rogers, H.A., Schut, L., Sposto, R., Timmons, C., Tomita, T., Trevenen, C., Vezina, G., Wisoff, J.H. and Boyett, J.M. (2012) ‘Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group’, Journal of Clinical Oncology, 30(21), pp. 2641–2647. https://doi.org/10.1200/JCO.2011.39.5642.
12. Pfister, S.M., Korshunov, A., Kool, M., Hasselblatt, M., Eberhart, C.G., Jabado, N., Sturm, D., Jones, D.T.W., Zheludkova, O., Siegel, P., Johann, P.D., Reuss, D., Capper, D., von Deimling, A., Crisman, T., Scheurlen, W., Roggendorf, W., Milde, T., Schuhmann, M.U., Kuhl, J., Felsberg, J., Reifenberger, G., Herold-Mende, C., Kulozik, A., von Bueren, A.O., Witt, O., Hovestadt, V., Tzaridis, T., Sill, M., Martin, D., Bader, S., Remke, M., Northcott, P.A., Taylor, M.D., Witt, H., Weber, U.D., Zapatka, M., Radlwimmer, B., Lichter, P., Korshunov, A. and Pfister, S.M. (2008) ‘Molecular diagnostics of CNS tumors: the Heidelberg experience’, Acta Neuropathologica, 116(2), pp. 197–208. https://doi.org/10.1007/s00401-008-0397-4.
13. Rodrigues, F.D., Gimple, R.C., Bender, S., Nazarian, J., Hargrave, D., Hawkins, C., Jones, D.T.W., Korshunov, A., Lambert, S.R., Li, Y., Majewski, J., Pfister, S.M., Tabori, U., Zadeh, G., Bouffet, E. and Jabado, N. (2021) ‘Challenges and opportunities in pediatric low-grade gliomas’, Nature Reviews Clinical Oncology, 18(4), pp. 213–229. https://doi.org/10.1038/s41571-020-00454-5.
14. Pollack, I.F., Jakacki, R.I., Butterfield, L.H., Hamilton, R.L., Lavey, R.S., Kun, L.E., Schut, L., Prados, M.D., Packer, R.J., Fouladi, M., Goldman, S., Geyer, J.R., Boyett, J.M. and the Children’s Oncology Group (2019) ‘Age-dependent incidence and clinical behavior of pilocytic astrocytoma: a Children’s Oncology Group study’, Neuro-Oncology, 21(11), pp. 1470–1480. https://doi.org/10.1093/neuonc/noz095.
15. Gutmann, D.H., Ferner, R.E., Listernick, R.H., Korf, B.R., Wolters, P.L. and Johnson, K.J. (2017) ‘Neurofibromatosis type 1’, Nature Reviews Disease Primers, 3, p. 17004. https://doi.org/10.1038/nrdp.2017.4.
16. Children’s Oncology Group (2023) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 6.0. Available at: https://www.survivorshipguidelines.org/ (Accessed: 15 October 2023).
17. Brat, D.J., Aldape, K., Colman, H., Figarella-Branger, D., Fuller, G.N., Giannini, C., Hawkins, C., Jain, D., Korshunov, A., Ng, H.K., Perry, A., Reifenberger, G., Rodriguez, F.J., Scheithauer, B.W., Smith, A.B., Tihan, T., von Deimling, A., Wesseling, P. and Louis, D.N. (2020) ‘cIMPACT-NOW update 5: recommended grading criteria and terminology for IDH-mutant astrocytomas’, Brain Pathology, 30(3), pp. 626–633. https://doi.org/10.1111/bpa.12816. Context for grading distinctions.
18. Schindler, G., Capper, D., Meyer, J., Janzarik, W.G., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., Louis, D.N., Ohgaki, H., von Deimling, A. and Korshunov, A. (2011) ‘BRAF V600E mutation analysis of 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma’, Acta Neuropathologica, 121(3), pp. 397–405. https://doi.org/10.1007/s00401-011-0802-8.
19. Lange, J., Hovestadt, V., Jones, D.T.W., Sturm, D., Pfister, S.M. and Korshunov, A. (2017) ‘Molecular pathology of pilocytic astrocytoma’, Acta Neuropathologica, 133(3), pp. 337–349. https://doi.org/10.1007/s00401-017-1684-7.
20. Merchant, T.E., Li, C., Xiong, X., Kun, L.E., Boop, F.A. and Sanford, R.A. (2009) ‘Conformal radiotherapy for pediatric low-grade glioma: clinical outcomes and cognitive function’, Journal of Clinical Oncology, 27(22), pp. 3691–3697. https://doi.org/10.1200/JCO.2008.20.5007.